Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Poulomee Bose"'
Autor:
Camila Pará, Poulomee Bose, Luigi Bruno, Erika Freemantle, Mahsa Taherzadeh, Xuefang Pan, Chanshuai Han, Peter S. McPherson, Jean-Claude Lacaille, Éric Bonneil, Pierre Thibault, Claire O’Leary, Brian Bigger, Carlos Ramon Morales, Graziella Di Cristo, Alexey V. Pshezhetsky
Publikováno v:
JCI Insight, Vol 6, Iss 15 (2021)
The majority of patients affected with lysosomal storage disorders (LSD) exhibit neurological symptoms. For mucopolysaccharidosis type IIIC (MPSIIIC), the major burdens are progressive and severe neuropsychiatric problems and dementia, primarily thou
Externí odkaz:
https://doaj.org/article/410c3252a7a24808ba1808d744c3aabd
Autor:
Poulomee Bose
Publikováno v:
Neural Regeneration Research, Vol 15, Iss 6, Pp 1041-1042 (2020)
Externí odkaz:
https://doaj.org/article/fb41e5a0d1f943718c4a8f2208ab5d1a
Publikováno v:
PLoS ONE, Vol 9, Iss 5, p e86970 (2014)
Nucleus accumbens (nAcb), a major site of action of drugs of abuse and dopamine (DA) signalling in MSNs (medium spiny neurons), is critically involved in mediating behavioural responses of drug addiction. Most studies have evaluated the effects of DA
Externí odkaz:
https://doaj.org/article/bb26e31f83164910a9eec9b6df395cbe
Autor:
Xuefang Pan, Mahsa Taherzadeh, Poulomee Bose, Rachel Heon-Roberts, Annie L.A. Nguyen, TianMeng Xu, Camila Pará, Yojiro Yamanaka, David A. Priestman, Frances M. Platt, Shaukat Khan, Nidhi Fnu, Shunji Tomatsu, Carlos R. Morales, Alexey V. Pshezhetsky
The majority of mucopolysaccharidosis IIIC (MPS IIIC) patients have missense variants causing misfolding of heparan sulfate acetyl-CoA:α-glucosaminide N-acetyltransferase (HGSNAT), which are potentially treatable with pharmacological chaperones. To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d581a89a1cd7814afc25e275b4725b1
https://doi.org/10.1084/jem.20211860
https://doi.org/10.1084/jem.20211860
Autor:
Mahsa Taherzadeh, Frances M. Platt, Alexey V. Pshezhetsky, Annie L. A. Nguyen, Shunji Tomatsu, Yojiro Yamanaka, Carlos R. Morales, David A. Priestman, Xuefang Pan, Shaukat Khan, Rachel Heon-Roberts, Camila Pará, TianMeng Xu, Poulomee Bose, Nidhi Fnu
ObjectiveOver 55% of mucopolysaccharidosis IIIC (MPS IIIC) patients have at least one allelic missense variant responsible for misfolding of heparan sulfate acetyl-CoA:α-glucosaminide N- acetyltransferase (HGSNAT). These variants are potentially tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93e0884da37aefd4e3bac5aa5e3908e8
https://doi.org/10.1101/2021.08.26.457793
https://doi.org/10.1101/2021.08.26.457793
Publikováno v:
Molecular Genetics and Metabolism. 135:S85
Autor:
Carlos R. Morales, Jean-Claude Lacaille, Erika Freemantle, Chanshuai Han, Camila Pará, Graziella Di Cristo, Claire O'Leary, Pierre Thibault, Mahsa Taherzadeh, Brian W. Bigger, Poulomee Bose, Xuefang Pan, Peter S. McPherson, Luigi Bruno, Eric Bonneil, Alexey V. Pshezhetsky
Publikováno v:
JCI Insight
The majority of patients affected with lysosomal storage disorders (LSD) exhibit neurological symptoms. For mucopolysaccharidosis type IIIC (MPSIIIC), the major burdens are progressive and severe neuropsychiatric problems and dementia, primarily thou
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 3, p 616 (2020)
Journal of Clinical Medicine
Journal of Clinical Medicine
About two thirds of the patients affected with lysosomal storage diseases (LSD) experience neurological manifestations, such as developmental delay, seizures, or psychiatric problems. In order to develop efficient therapies, it is crucial to understa
Autor:
Poulomee Bose, Elsa Tremblay, Claudia Maios, Vijay Narasimhan, Gary A. B. Armstrong, Meijiang Liao, J. Alex Parker, Richard Robitaille, Xiao Yan Wen, Christopher Barden, Pierre Drapeau
Publikováno v:
Neurotherapeutics. 18:2128-2128
Autor:
Gary A. B. Armstrong, Poulomee Bose, Christopher Barden, Claudia Maios, J. Alex Parker, Vijay Narasimhan, Richard Robitaille, Xiao-Yan Wen, Meijiang Liao, Elsa Tremblay, Pierre Drapeau
Publikováno v:
Neurotherapeutics
Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disorder in which the neuromuscular junction progressively degenerates, leading to movement difficulties, paralysis, and eventually death. ALS is currently being treated by only
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e83ce053bfcebbef6363ad766f1f08c6
https://europepmc.org/articles/PMC6985319/
https://europepmc.org/articles/PMC6985319/